Loading organizations...

Growth capital investor providing patient, minority equity investments and growth support for multi-sector SMEs and startups in the UK and Ireland.
Get email updates
Join 25K+ founders & VCs who start their week informed.
BGF is a London, United Kingdom-based investment firm that provides patient, minority equity capital to small and mid-sized enterprises across the UK and Ireland. Operating with an evergreen £3 billion balance sheet, the firm typically deploys between £1 million and £20 million per transaction without taking controlling stakes in its target companies. The organization employs over 150 people and has invested more than £4.5 billion into over 600 businesses across various sectors, including technology, healthcare, and manufacturing. BGF is funded by a consortium of major financial institutions, including Barclays, HSBC, Lloyds Banking Group, NatWest, and Standard Chartered. Its active and exited portfolio features notable scaleups such as Gousto, Kids Planet, Amdaris, and OrganOx. The firm was founded in 2011 by a consortium of the UK's largest banks to stimulate regional economic growth following the financial crisis.
Key people at BGF.
BGF (Business Growth Fund) is a UK‑and‑Ireland growth capital investor that provides long‑term, minority equity investments and value‑creation support to small and mid‑sized businesses, with a regional, patient‑capital focus and a track record of several hundred portfolio companies and billions deployed.[1][2]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech and Growth Landscape
Quick Take & Future Outlook
Quick reminder: the above synthesizes public profiles and BGF’s own descriptions of activity and strategy; specific deal terms, fund sizes and future commitments are periodically updated by BGF and regulators and should be checked on their website or filings for the latest figures.[2][5]
Key people at BGF.
BGF has more than 26 tracked investments across 25 companies. The latest tracked deal is $40.0M Series A in Cellular Origins in December 2025.